about
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyMechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.Noncanonical roles of the immune system in eliciting oncogene addictionClinical applications of natural killer T cell-based immunotherapy for cancer.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.Combination immune therapies to enhance anti-tumor responses by NK cells.TRAIL on trial: preclinical advances in cancer therapyUnravelling the complexity of cancer-immune system interplay.Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice.
P2860
Q28235277-FDD246B6-51F1-412F-96C4-B66F2A445022Q33606150-04633FB7-E158-489F-A1C3-4E7C108D520DQ36220613-E0E2F1B1-D919-496B-88AC-A83364226D5EQ36931816-0872A401-BD72-4892-B979-221C50E52D3EQ37092313-DB3CB884-8855-41B2-879F-640263E91A01Q37114025-AC028184-4151-40E7-A103-34BED55E01BAQ37273138-92DCAA95-CA8D-4383-8ABA-F1F6EA1FEDC3Q37408550-D60FB242-F73B-4721-B366-DB709C42EC5AQ37433463-F6FDCB3F-FF3A-4491-BFDA-15F8F4FF4A4EQ37765590-1CAA347F-381D-4662-B6C6-77530103CCCFQ39748254-6084969C-FD11-4EA6-8D3D-BB6932383BF3Q42721429-E8F6CDEB-FF42-40B5-A180-0AB437ABA42D
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combination antibody-based cancer immunotherapy.
@en
type
label
Combination antibody-based cancer immunotherapy.
@en
prefLabel
Combination antibody-based cancer immunotherapy.
@en
P1433
P1476
Combination antibody-based cancer immunotherapy.
@en
P2093
Kazuyoshi Takeda
Ko Okumura
P304
P356
10.1111/J.1349-7006.2007.00529.X
P577
2007-06-08T00:00:00Z